- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06468748
The Effects of Semaglutide on Body Composition and Performance in Military Personnel
The Effects of a GLP-1R Agonist (the Drug Wegovy®) on Body Composition and Performance in Military Personnel
Study Overview
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- USARIEM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Active-duty military personnel
- Age ≥ 18 years at the time of signing informed consent.
- Body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 with the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, etc.)
- History of at least one self-reported effort to lose body weight.
- Ability to exercise ≥ 3x per week during the study.
Exclusion Criteria:
- Currently in Basic Combat Training, Advanced Individual Training, or One Station Unit Training, or equivalence in other military services.
- Current or history of Type 1 or Type 2 Diabetes, cardiovascular (e.g., heart disease, peripheral artery disease), musculoskeletal (e.g., myopathies), immune (e.g., lupus, asthma), gastrointestinal (e.g., irritable bowel syndrome, pancreatitis), neurological (e.g., dystonia), pulmonary (pulmonary fibrosis, COPD, lung cancer), or renal diseases (e.g., kidney diseases), and eating disorders (e.g., bulimia nervosa, anorexia nervosa).
- History of cholecystectomy
- Personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia type 2.
- Participants who are pregnant or breastfeeding, or those who may be pregnant or were pregnant in the last 12 months.
- Male and female participants who plan or will attempt to become pregnant or help conceive a child within two months of treatment.
- Inability to exercise ≥ 3x per week during the study.
- Currently taking or history of routine use of medications known to affect metabolism or performance (e.g., thiazide diuretics, oral steroids, testosterone replacement therapy, etc.).
- Self-reported change in body weight ≥ 5 kg within 90 days before screening.
- Treatment with any medication for the indication of obesity within 90 days before screening.
- Treatment with other orally administered medications such as sulfonylureas, sitagliptin, phenytoin, levothyroxine, albuterol, prednisone, and other drugs as identified during screening by the medical screening and staff.
- Current or previously suspected alcohol abuse (defined as Harmful Use by the World Health Organization), those who meet criteria for alcohol abuse disorder (as outlined in the DSM-5), or other substance abuse (i.e., the use of illegal drugs or the use of prescription or over-the-counter drugs for purposes other than those for which they are meant to be used, or in excessive amounts.
- History of major depressive disorder.
- Participants with implanted or external electrical devices (e.g., pacemakers).
- On a specialized diet (e.g., keto, intermittent fasting).
- Claustrophobia or difficulty breathing with a face mask.
- Known or suspected hypersensitivity to study product(s) or related products.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Semaglutide Treatment
Semaglutide will be self-administered by participants with a prefilled pen injector on the same day each week, at any time of day, with or without meals. It will be initiated at a dose of 0.25 mg once weekly for the first 4 weeks, with the dose increased every 4 weeks to reach a maintenance dose of 2.4 mg weekly by week 16. They will remain on the maintenance dosage of 2.4mg until week 24. If participants cannot reach 2.4 mg/week they will stop at the maximal tolerable dose (e.g., 1.7 mg/week). After 24-weeks, treatment will be stopped, and participants will remain in the trial for 1 year with follow-up assessments at week 48 and week 76. |
During the first visit, participants will be taught how to self-administer the pen injector by medical staff.
Participants will also be provided instructions for self-administering injections and a compliance log to track adherence to the treatment, and additional information about each injection (date, time, injection site)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight Loss
Time Frame: 24 weeks
|
the amount of body weight loss in kilograms caused by semaglutide in 24 weeks.
|
24 weeks
|
|
Body composition
Time Frame: 24 weeks
|
the percentage of lean and fat mass loss during semaglutide treatment.
|
24 weeks
|
|
Physical Performance
Time Frame: 24 weeks
|
the percent change in VO2peak (mL/kg/min) during semaglutide treatment.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight Loss Maintenance
Time Frame: 76 weeks
|
if semaglutide results in maintenance of lower body weight in kilograms 52 weeks after cessation of treatment.
|
76 weeks
|
|
Eating habits and mediators of eating behavior
Time Frame: 76 weeks
|
the effects of semaglutide treatment on appetite, hunger, and food preferences measured by the military eating behavior scale during and after semaglutide treatment.
|
76 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone
Time Frame: 76 weeks
|
the effects of semaglutide treatment on bone volume/total volume during and after semaglutide treatment.
|
76 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 24-05H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.